These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 31955393)

  • 21. Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital.
    Caracuel F; Muñoz N; Baños U; Ramirez G
    J Oncol Pharm Pract; 2015 Jun; 21(3):163-9. PubMed ID: 24598374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
    McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Region-wide professional practice evaluation with regards to antiemetic prescription into chemotherapy-induced nausea and vomiting].
    Tavernier J; Jouannet-Romaszko M; Bertucat H; Marchiset N; Bahadoor M; Chevrier R
    Bull Cancer; 2016; 103(7-8):622-31. PubMed ID: 27178880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
    Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
    Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
    Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
    Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).
    Aapro M; Caprariu Z; Chilingirov P; Chrápavá M; Curca RO; Gales L; Grigorescu AC; Huszno J; Karlínová B; Kellnerová R; Malejčíková M; Marinca M; Petru E; Płużanski A; Pokorná P; Pribulova Z; Rubach M; Steger GG; Tesařová P; Valekova L; Yordanov N; Walaszkowska-Czyz A
    Eur J Cancer; 2022 May; 166():126-133. PubMed ID: 35290913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea.
    Lee R; Ku M; Je NK
    Support Care Cancer; 2024 Feb; 32(3):190. PubMed ID: 38400861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
    Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
    Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
    De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
    Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice.
    Badarudin NS; Mohamed Shah N; Mohd Kassim KNB; Ismail F; Islahudin F; Mohd Tahir NA; Yusak S
    Support Care Cancer; 2022 Jun; 30(6):5339-5349. PubMed ID: 35290510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
    Okuyama A; Nakamura F; Higashi T
    Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
    Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
    J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
    Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
    Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk.
    Fujii H; Iihara H; Ishihara M; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2013 Dec; 33(12):5549-56. PubMed ID: 24324096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
    Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
    Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.